Experts help bring first-of-its-kind drug for metabolic liver disease to the clinic

by

Liver disease specialists at the University of Chicago Medicine will soon begin prescribing a first-of-its-kind drug for treating advanced metabolic dysfunction-associated steatotic liver disease (MASLD)—formerly known as nonalcoholic fatty liver disease (NAFLD).

Leave A Comment

Your email address will not be published. Required fields are marked *